ClinicalTrials.gg
RecruitingNCT07778888BRIGHTUpdated Nov 10, 2026

BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial

A Phase 2 interventional study of BL1107 in Dry Eye Disease, sponsored by Bausch & Lomb Incorporated. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 10, 2026Now RecruitingFirst site in United States+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 25 studies in Dry Eye Syndromes by Bausch Health Companies Inc. — 1 open to participants now, 2 under way, none of them phase 3. Dry Eye Syndromes · Bausch Health Companies Inc..

Planned enrollment
22nd of 24
20 · median 112
Started
2026
the only one that year
Phase 2
8 of 25
1 open now
Registered
25th of 25
by date

Among the 25 studies in Dry Eye Syndromes by Bausch Health Companies Inc., this one is the 22nd largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2026, is one of 8 in phase 2, and was the 25th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

1 of the 25 studies in Dry Eye Syndromes by Bausch Health Companies Inc. is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Dry Eye Syndromes by Bausch Health Companies Inc., or all of them as a file.
02

Study summary

Trial RX01-BL1107-1202 is designed to identify the lowest effective concentration of BL1107 required for complete resolution of conjunctival hyperemia in participants with DED. Participants will be masked to concentration of BL1107 received.

03

Conditions studied

  • Dry Eye Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of dry eye disease
  • Conjunctival hyperemia in both eyes, without clinical signs of infection or allergic conjunctivitis

Exclusion criteria

Exclusion Criteria:

  • Any active ocular disease
  • Anticipated wearing of contact lenses during study

Additional criteria per protocol

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    BL1107 is sterile ophthalmic solution to be administered at varying concentrations

    Drug: BL1107

Interventions

  • DrugBL1107

    BL1107 topical ocular solution

06

What researchers measure

Primary outcomes

  1. Primary Part 1: Proportion of participants with complete resolution in conjunctival hyperemia at 30 minutes, in each evaluated concentration of BL1107.

    Time frame: Assessed at 30 minutes

  2. Primary Part 2: Proportion of participants with complete resolution in conjunctival hyperemia at 8 hours, in each evaluated concentration of BL1107

    Time frame: Assessed at 8 hours

07

Study locations

1 of 1 sites recruiting
  • Site 101
    Newport Beach, California 92663, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Feb 2027, 4 months after the start.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's planned 4 months is below that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2026
First posted
Aug 21, 2026
StartActual
Oct 19, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
1 site added — first site in United States
Show site
  • Site 101 · Newport Beach, United States
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Site 101 · Newport Beach, United States
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07778888
Responsible party
Sponsor
First posted
Aug 21, 2026
Start date
Oct 19, 2026
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Johnson Varughese
Contact
Johnson.Varughese@bausch.com
9089271162

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion